"I'm excited to welcome Mike to our talented executive team. With his proven track record in building and scaling great sales teams, and his commitment to customer success, Mike is a key addition to our leadership team as we enter a new phase of growth," stated Jagath Wanninayake, CEO of Suvoda.
FREMONT, CA: Suvoda, an innovator in clinical trial software, declared the appointment of Mike Davies as its Senior Vice President of Global Sales. Mike will spearhead the worldwide sales organization serving the company's customers in the EMEA, US, and APAC during the company's rapid growth and international expansion.
"I'm excited to welcome Mike to our talented executive team. With his proven track record in building and scaling great sales teams, and his commitment to customer success, Mike is a key addition to our leadership team as we enter a new phase of growth," stated Jagath Wanninayake, CEO of Suvoda.
Davies is an accomplished sales leader with vast experience in technology solutions in the Life Sciences industry. Recently he was vice president of sales in the R&D group at Veeva Systems, where he played a major role in helping establish global market leadership in software applications for Regulatory, Clinical, and Quality. Before Veeva, he served as vice president of global sales at TraceLink, a pharmaceutical supply chain software company where he built their global sales organization and drove triple-digit sales growth during his tenure. Davies was also previously appointed as the vice president of global sales in the Health Sciences Global Business Unit at Oracle. Davies started his career at Parke Davis. He holds a bachelor's degree in pharmacology from Sunderland University and a doctorate in pharmacology from the University of Bradford, in the UK.
"Suvoda has rapidly established itself as a leader in solving Life Sciences companies' complex randomization and clinical supply chain challenges," said Davies. "This is a tremendous opportunity to join an outstanding team with a vision to propel our customers and the industry to the next level of clinical trial transformation."
